[Source: GEN] – Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.
To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.
For more information: Revalesio Partners with Leading Firm